Stockscreener 앱 받기
12.53
6.01%
0.71
시간 외 거래:
12.50
-0.03
-0.24%
전일 마감가:
$11.82
열려 있는:
$11.83
하루 거래량:
11.23M
Relative Volume:
1.86
시가총액:
$9.12B
수익:
$158.30M
순이익/손실:
$4.74B
주가수익비율:
-9.3507
EPS:
-1.34
순현금흐름:
$-710.11M
1주 성능:
+11.88%
1개월 성능:
+6.82%
6개월 성능:
+10.98%
1년 성능:
+39.22%
1일 변동 폭
$11.78
$12.57
1주일 범위
$11.04
$12.57
52주 변동 폭
$8.611
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
ROIV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ROIV | 12.53 | 9.12B | 158.30M | 4.74B | -710.11M | -1.34 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Roivant Sciences president Eric Venker sells $1.13 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences president Eric Venker sells $1.13 million in shares - Investing.com
Thompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution - Yahoo Finance
Principal Financial Group Inc. Trims Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Vivek Ramaswamy's Net Worth Is 9 Figures—See How the DOGE Co-Lead Made His Millions - Yahoo Finance
Andreas Halvorsen's Recent Transaction in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences Ltd. (ROIV) Quarterly 10-Q Report - Quartzy
Vivek Ramaswamy: 10 things you ought to know about Trump's DOGE co-lead - MSN
Roivant Sciences Ltd - Reuters
Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trump’s appointment of Ramaswamy sparks speculation on Korean biotech firms linked to Roivant - KBR
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new "Department of Government Efficiency" (DOGE) - MSN
From Vadakkanchery to top US Govt post: Vivek Ramaswamy's Kerala roots - Mathrubhumi English
The Analyst Landscape: 5 Takes On Roivant Sciences - Benzinga
How Vivek Ramaswamy Became A Billionaire - Forbes
Who is Vivek Ramaswamy? What to know about Cincinnati billionaire part of Trump's Cabinet - The Cincinnati Enquirer
Vivek Ramaswamy Net Worth 2024: How He Built a Billion-Dollar Empire - Black Star News
Vivek Ramaswamy's journey from bright son of immigrants to being Donald Trump's pick - The Economic Times
Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Call Transcript - Insider Monkey
Vivek Ramaswamy Net Worth 2024: Salary, Net Worth in Rupees (INR), Annual Income, Houses, and Cars. - Jagran Josh
Who Is Vivek Ramaswamy, The Biotech Entrepreneur Now Part Of Trump 2.0 - NDTV
Vivek Ramaswamy Net Worth: How this key Trump aide built his billion-dollar empire - Moneycontrol
Who is Vivek Ramaswamy? Know about his early life, education, and role as head of the new 'Department of - The Times of India
Roivant Sciences Ltd (ROIV) Q2 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Vivek Ramaswamy Net Worth: From Transforming 'Ailing' Pharma To Betting On Crypto; How Trump’s Key Aide Built His Empire - Jagran English
FMR LLC Bolsters Stake in Roivant Sciences Ltd - GuruFocus.com
Roivant Sciences Reports Q2 2024 Financial Results - TipRanks
Roivant Sciences earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Vivek Ramaswamy's Net Worth: How Harvard-Yale graduate became rich by selling 'sick' pharma companies - The Economic Times
Vivek Ramaswamy Net Worth: How Much Money Does the Co-Director of D.O.G.E Have? - Revista Merca2.0
Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 2c - StreetInsider.com
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update - The Manila Times
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: Wha - GuruFocus.com
ROIVWroivw Latest Stock News & Market Updates - StockTitan
Vanguard Group Inc's Strategic Acquisition in Roivant Sciences L - GuruFocus.com
Roivant Sciences (ROIV) to Release Earnings on Tuesday - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by Impax Asset Management Group plc - MarketBeat
Allspring Global Investments Holdings LLC Sells 115,694 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 - Yahoo Finance
Organon Completes Acquisition of Dermavant - njbmagazine.com
China Universal Asset Management Co. Ltd. Boosts Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Organon completes Dermavant Sciences acquisition By Investing.com - Investing.com Canada
Organon completes Dermavant Sciences acquisition - Investing.com
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% - StockTitan
At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K - Benzinga
Options Exercise: Eric Venker At Roivant Sciences Realizes $782K - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares - MarketBeat
Roivant Sciences president sells $1.17 million in shares By Investing.com - Investing.com Australia
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & COO |
Nov 20 '24 |
Sale |
11.32 |
100,000 |
1,132,000 |
606,525 |
1.89%
2.08%
자본화:
|
볼륨(24시간):